Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Johns Hopkins University · Johns Hopkins Medicine · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
821
total citations
- FWCI
- 40.41
- Percentile
- 100%
- References
- 14
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Fingolimod
- Medicine
- Placebo
- Multiple sclerosis
- Internal medicine
- Clinical endpoint
- Relapsing remitting
- Adverse effect
UN Sustainable Development Goals
- Peace, Justice and strong institutions
No related works found for this paper.